Rosiglitazone · Avandia

Small molecule

WithdrawnUS approval

Evidence outlook · regulatory status

US approval withdrawn: Type 2 Diabetes (FDA, approved 1999-05-25)

The FDA approved this product and later withdrew the approval, so it has no current US approval. The withdrawal took effect on 2025-09-03. The holder told FDA the product was no longer marketed and asked FDA to withdraw the approval (21 CFR 314.150(c)); FDA states that such a withdrawal is without prejudice to refiling. Development was discontinued on 2025-09-03, as a strategic decision by the sponsor. The trials below are the product's evidence history.

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (41)
Other / comorbidity
NCT00240604 · Hadassah Medical Organization
2005-04 – 2015-10 · Glucose Intolerance
What this study did
NCT00349427 · GlaxoSmithKline
started 2005-10 · Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2
What this study did
NCT01574820 · National Cheng-Kung University Hospital
2006-11 – 2011-07 · Prediabetes, Coronary Artery Disease, Insulin Resistance, Glucose Intolerance
What this study did
NCT01453049 · GlaxoSmithKline
2010-04 – 2010-10 · Diabetes Mellitus, Type 2
What this study did
NCT00116922 · Samuel Lunenfeld Research Institute, Mount Sinai Hospital
2004-06 – 2010-01 · Impaired Glucose Tolerance, Diabetes
What this study did
NCT00490568 · GlaxoSmithKline
2007-08-08 – 2009-06-01 · Alzheimer's Disease
What this study did
NCT00348140 · GlaxoSmithKline
2006-07-12 – 2009-03-20 · Alzheimer's Disease
What this study did
NCT00550420 · GlaxoSmithKline
2007-10-01 – 2009-02-12 · Alzheimer's Disease
What this study did
NCT00379769 · GlaxoSmithKline
2001-04 – 2008-12 · Diabetes Mellitus, Type 2
What this study did
NCT00428090 · GlaxoSmithKline
2007-02-27 – 2008-09-05 · Alzheimer's Disease
What this study did
NCT00135330 · AstraZeneca
2005-10 – 2008-07 · Diabetes Mellitus, Type 2
What this study did
NCT00032487 · VA Office of Research and Development
2000-12-01 – 2008-05-30 · Type 2 Diabetes Mellitus
What this study did
NCT00452166 · Leiden University Medical Center
2007-04 – 2008-05 · Chronic Kidney Disease, Insulin Resistance
What this study did
NCT00427154 · Novo Nordisk A/S
2007-01-10 – 2008-03-11 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00348712 · Novo Nordisk A/S
2006-10-30 – 2008-03-05 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00131664 · Canadian Heart Research Centre
2005-09 – 2008-01 · Type 2 Diabetes Mellitus
What this study did
NCT00409097 · Amsterdam UMC, location VUmc
2006-04 – 2007-12 · Critical Illness, Multiple Organ Failure
What this study did
NCT00399711 · Novo Nordisk A/S
2006-11 – 2007-11 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00203632 · University of Calgary
2003-09 – 2007-10 · Diabetes Mellitus
What this study did
NCT00333151 · Novo Nordisk A/S
2006-05 – 2007-08 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00465296 · Medstar Health Research Institute
2006-01 – 2007-07 · Metabolic Syndrome
What this study did
NCT00169832 · Laval University
2003-06 – 2007-07 · Diabetes, Coronary Artery Bypass Grafting
What this study did
NCT00297063 · GlaxoSmithKline
2006-01-11 – 2007-05-31 · Diabetes Mellitus, Type 2
What this study did
NCT00318422 · Novo Nordisk A/S
2006-05 – 2007-05 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00523913 · GlaxoSmithKline
2005-11 – 2007-04 · Diabetes Mellitus, Type 2
What this study did
NCT00432679 · GlaxoSmithKline
2006-05-24 – 2007-03-28 · Diabetes Mellitus, Type 2
What this study did
NCT00095654 · Gerstein, Hertzel, MD
2001-07 – 2006-10 · Impaired Glucose Tolerance, Cardiovascular Disease, Glucose Metabolism Disorders
What this study did
NCT00140647 · Gerstein, Hertzel, MD
2001-07 – 2006-07 · Atherosclerosis, Impaired Glucose Tolerance, Isolated Impaired Fasting Glucose, Cardiovascular Disease
What this study did
NCT00489229 · Universiti Sains Malaysia
2002-10 – 2005-12 · Diabetes, Impaired Glucose Tolerance
What this study did
NCT00422955 · GlaxoSmithKline
2003-11 – 2005-10 · Neuropathy, Diabetic
What this study did
NCT00123227 · Royal Brompton & Harefield NHS Foundation Trust
2002-10 – 2005-05 · Diabetes Mellitus, Type 2, Vascular Diseases, Hypertension
What this study did
NCT00231387 · GlaxoSmithKline
2002-09 – 2005-05 · Non-insulin-dependent Diabetes Mellitus
What this study did
NCT00499707 · GlaxoSmithKline
2003-10-08 – 2004-12-16 · Diabetes Mellitus, Type 2
What this study did
NCT00067951 · GlaxoSmithKline
2003-10-17 – 2004-11-30 · Diabetes Mellitus, Type 2
What this study did
NCT00069836 · GlaxoSmithKline
2003-10 – 2004-11 · Diabetes Mellitus, Type 2
What this study did
NCT00182052 · Massachusetts General Hospital
2000-09 – 2003-08 · Adenocarcinoma of the Prostate, Prostate Cancer
What this study did
NCT00197132 · GlaxoSmithKline
2002-10 – 2003-08 · Insulin Resistance
What this study did
Phase 2/3 (6)
Other / comorbidity
NCT00831129 · University of Chicago
2006-09 – 2011-04 · Pre-diabetes
What this study did
NCT00169923 · Leiden University Medical Center
2007-04 – 2009-05 · Chronic Kidney Disease, Inflammation
What this study did
NCT04148183 · J JESUS VENEGAS, MD
2004-01-01 – 2009-01-01 · Insulin Resistance
What this study did
NCT00121953 · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
2005-07 – 2008-05 · Endometriosis
What this study did
NCT00119496 · University of Glasgow
2005-07 – 2007-06 · Asthma
What this study did
NCT00116792 · Gold, Herman K., MD
started 2004-03 · Coronary Artery Disease, Diabetes Mellitus
What this study did
Phase 2 (30)
Other / comorbidity
NCT04114136 · Dan Zandberg
2020-09-14 – 2032-04-30 · Melanoma, NSCLC, Hepatocellular Carcinoma, Urothelial Cancer, Gastric Adenocarcinoma, HNSCC, Esophageal Adenocarcinoma, Microsatellite Instability-High Solid Malignant Tumor
What this study did
NCT00004180 · Dana-Farber Cancer Institute
1999-10 – 2015-05 · Sarcoma
What this study did
NCT00242593 · University of Washington
2006-06 – 2011-12 · Mild Cognitive Impairment
What this study did
NCT00618072 · New York Medical College
2008-01 – 2011-01 · Hyperinsulinemia, Insulin Resistance, Obesity
What this study did
NCT00612066 · Jonsson Comprehensive Cancer Center
2007-04 – 2010-11 · Cushing's Disease
What this study did
NCT00616642 · Jonsson Comprehensive Cancer Center
2006-10 – 2010-11 · Brain and Central Nervous System Tumors
What this study did
NCT00098852 · University of California, San Francisco
2004-10 – 2010-06 · Head and Neck Cancer
What this study did
NCT01150981 · University of Massachusetts, Worcester
2006-11 – 2010-04 · Metabolic Syndrome, Insulin Resistance
What this study did
NCT00614874 · Creighton University
2008-12 – 2010-03 · Asthma
What this study did
NCT00609362 · University of Aarhus
2008-01 – 2009-11 · Change in Bone Mineral Density, Change in Bone Marrow Fat Content
What this study did
NCT00699036 · Brooke Army Medical Center
2007-04 – 2009-08 · Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver Disease
What this study did
NCT00381238 · GlaxoSmithKline
2006-06-20 – 2009-02-03 · Alzheimer's Disease
What this study did
NCT00367744 · National Institute of Allergy and Infectious Diseases (NIAID)
2006-07 – 2008-12 · HIV Infections
What this study did
NCT00405015 · Radboud University Medical Center
2007-04 – 2008-10 · Ischemia-Reperfusion Injury, The Metabolic Syndrome
What this study did
NCT00370305 · Charite University, Berlin, Germany
2004-05 – 2008-10 · Metabolic Syndrome, Impaired Glucose Tolerance
What this study did
NCT00094796 · National Heart, Lung, and Blood Institute (NHLBI)
2004-10-20 – 2008-09-03 · Diabetes Mellitus, Type II, Insulin Resistance
What this study did
NCT00265148 · GlaxoSmithKline
2004-05-18 – 2008-07-10 · Alzheimer's Disease
What this study did
NCT00065065 · James Lewis
2002-09 – 2008-01 · Ulcerative Colitis, Inflammatory Bowel Disease
What this study did
NCT00110851 · Wellstat Therapeutics
2005-04 – 2007-08 · Type 2 Diabetes Mellitus
What this study did
NCT00369174 · National Cancer Institute (NCI)
2006-06 – 2007-08 · Oral Leukoplakia
What this study did
NCT00309309 · Mario Negri Institute for Pharmacological Research
2005-04 – 2007-07 · Kidney Transplant
What this study did
NCT00334568 · GlaxoSmithKline
2004-12 – 2007-07 · Alzheimer's Disease
What this study did
NCT00492700 · Association pour la Recherche sur les Maladies Hépatiques Virales
started 2003-01 · Non Alcoholic Steatohepatitis
What this study did
NCT01577095 · China Medical University Hospital
2006-04 – 2007-05 · Type 2 Diabetes Mellitus With Features of Insulin Resistance
What this study did
NCT00064727 · National Heart, Lung, and Blood Institute (NHLBI)
2003-07-09 – 2007-04-11 · Congestive Heart Failure
What this study did
NCT00178841 · Vanderbilt University
2005-06 – 2007-03 · Cutaneous T-cell Lymphoma, Mycosis Fungoides, Sezary Syndrome
What this study did
NCT00115661 · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
2005-07 – 2006-05 · Endometriosis
What this study did
NCT00006493 · National Center for Research Resources (NCRR)
— · HIV Infections, Hyperlipidemia
What this study did
NCT00015626 · National Center for Research Resources (NCRR)
— · Insulin Resistance, Diabetes Mellitus
What this study did
NCT00018382 · US Department of Veterans Affairs
1999-10 – 2003-03 · Alzheimer Disease
What this study did
Phase 1/2 (3)
Other / comorbidity
NCT00130286 · Weill Medical College of Cornell University
2005-03 – 2010-08 · HIV-Associated Lipodystrophy Syndrome, Insulin Resistance, HIV Infections, Metabolic Syndrome X, Body Weight Changes
What this study did
NCT00309660 · Herlev Hospital
2005-11 – 2007-06 · Ulcerative Colitis
What this study did
NCT00149383 · Mahidol University
2004-12 – 2006-01 · Falciparum Malaria
What this study did
Phase 1 (24)
Other / comorbidity
NCT01287598 · Bayer
2011-08-02 – 2018-07-30 · Neoplasms
What this study did
NCT01100619 · Exelixis
2010-04 – 2012-08 · Papillary Thyroid Cancer, Follicular Thyroid Cancer, Huerthle Cell Thyroid Cancer, Renal Cell Carcinoma
What this study did
NCT00607945 · Ohio State University
2008-01 – 2012-05 · Type 2 Diabetes Mellitus
What this study did
NCT00443170 · GlaxoSmithKline
started 2006-11 · Healthy Subjects, Anaemia
What this study did
NCT00964106 · GlaxoSmithKline
2009-08-26 – 2011-08-29 · Drug Interactions
What this study did
NCT01402076 · Vanda Pharmaceuticals
2011-08 – 2011-08 · Healthy Volunteers
What this study did
NCT01415128 · VIVUS LLC
2010-04 – 2010-05 · Erectile Dysfunction
What this study did
NCT01088594 · Solvay Pharmaceuticals
2010-02 – 2010-03 · Type 2 Diabetes Mellitus
What this study did
NCT01332071 · GlaxoSmithKline
2009-11-24 – 2009-12-06 · Diabetes Mellitus, Type 2
What this study did
NCT00811356 · GlaxoSmithKline
2008-12-11 – 2009-03-30 · Malaria
What this study did
NCT01872780 · Inje University
2008-08 – 2009-03 · Healthy
What this study did
NCT00733785 · GlaxoSmithKline
2008-08-13 – 2008-11-28 · Alzheimer's Disease
What this study did
NCT00785213 · Mutual Pharmaceutical Company, Inc.
2008-09 – 2008-10 · Healthy
What this study did
NCT00551564 · GlaxoSmithKline
2007-07-31 – 2008-09-08 · Diabetes Mellitus, Type 2
What this study did
NCT00688207 · GlaxoSmithKline
2008-04 – 2008-09 · Alzheimer's Disease
What this study did
NCT00615212 · GlaxoSmithKline
2008-01-02 – 2008-02-15 · Diabetes Mellitus, Type 2
What this study did
NCT00193648 · Northwell Health
2005-07 – 2007-10 · Focal Glomerulosclerosis
What this study did
NCT00511823 · GlaxoSmithKline
2007-07-23 – 2007-09-21 · Nausea and Vomiting, Chemotherapy-Induced
What this study did
NCT00468897 · GlaxoSmithKline
2007-03-21 – 2007-05-02 · Alzheimer's Disease
What this study did
NCT00362726 · Bristol-Myers Squibb
2006-09 – 2006-11 · HIV Infections
What this study did
NCT00318630 · GlaxoSmithKline
2005-07-22 – 2006-06-30 · Asthma
What this study did
NCT00039663 · National Institutes of Health Clinical Center (CC)
2002-05 – 2005-10 · HIV Infections
What this study did
NCT00006185 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
1999-09 – 2003-08 · HIV Infections, Lipodystrophy, Insulin Resistance
What this study did
Phase 4 (42)
Other / comorbidity
NCT00640224 · Silva Arslanian
2005-03 – 2015-07 · Polycystic Ovary Syndrome
What this study did
NCT01406704 · Seoul St. Mary's Hospital
2004-01 – 2013-12 · NASH (Non-alcoholic Steato-hepatitis)
What this study did
NCT00953498 · Centre Hospitalier Universitaire Dijon
2007-10 – 2012-03 · Type 2 Diabetes
What this study did
NCT00337350 · Massachusetts General Hospital
2003-09 – 2011-01 · Schizophrenia
What this study did
NCT00879970 · GlaxoSmithKline
2009-05 – 2010-11 · Diabetes Mellitus, Type 2
What this study did
NCT00679939 · GlaxoSmithKline
2008-04-21 – 2010-09-16 · Diabetes Mellitus, Type 2
What this study did
NCT00207402 · Brooke Army Medical Center
2005-10 – 2010-07 · Hepatitis C
What this study did
NCT00738023 · Emory University
2004-03 – 2009-12 · Type 2 Diabetes, Hypertension
What this study did
NCT00733174 · Denver Research Institute
2004-03 – 2009-01 · Impaired Glucose Tolerance
What this study did
NCT00367055 · GlaxoSmithKline
2004-10 – 2008-10 · Type 2 Diabetes Mellitus
What this study did
NCT00373178 · Aristotle University Of Thessaloniki
2005-01 – 2008-06 · Type 2 Diabetes Mellitus
What this study did
NCT00522470 · Baskent University
— · Type 2 Diabetes Mellitus, Obesity
What this study did
NCT00567593 · James Lewis
2007-10 – 2008-03 · Inflammatory Bowel Disease
What this study did
NCT00746174 · University of Texas Southwestern Medical Center
2004-02 – 2008-02 · Insulin Sensitivity
What this study did
NCT00343395 · Intermountain Health Care, Inc.
2006-06 – 2008-01 · Coronary Artery Disease
What this study did
NCT00274495 · Beth Israel Medical Center
2006-01 – 2007-10 · Chronic Hepatitis C Infection, Fatty Liver
What this study did
NCT00318656 · GlaxoSmithKline
2005-11 – 2007-10 · Non-Insulin-Dependent Diabetes Mellitus
What this study did
NCT00571506 · University of Arkansas
2004-05 – 2007-08 · Diabetes Mellitus, Type 2, Vascular Diseases
What this study did
NCT00121966 · Odense University Hospital
2003-01 – 2007-07 · Type 2 Diabetes Mellitus
What this study did
NCT00424762 · University of Texas Southwestern Medical Center
2005-02 – 2007-04 · Diabetes Mellitus, Type 2
What this study did
NCT00675740 · University of Leipzig
2004-01 – 2007-02 · Impaired Glucose Tolerance
What this study did
NCT00314561 · Korea University Anam Hospital
2006-05 – 2006-12 · Metabolic Syndrome
What this study did
NCT00225355 · University of Glasgow
2006-02 – 2006-11 · Angina Pectoris, Metabolic Syndrome X
What this study did
NCT00306176 · Aristotle University Of Thessaloniki
2005-01 – 2006-10 · Type II Diabetes Mellitus
What this study did
NCT00364221 · University of Colorado, Denver
2004-11 – 2006-10 · Metabolic Syndrome, Insulin Resistance
What this study did
NCT00225342 · University of Glasgow
— · Angina Pectoris, Diabetes Mellitus, Type 2
What this study did
NCT00300911 · Baskent University
started 2005-12 · Diabetes Mellitus, Type 2
What this study did
NCT00440375 · Baskent University
2005-06 – 2006-03 · Type 2 Diabetes Mellitus, Obesity, Menopause
What this study did
NCT00241605 · GlaxoSmithKline
2003-06-25 – 2005-12-16 · Diabetes Mellitus, Type 2
What this study did
NCT00123643 · St. Paul Heart Clinic
2003-05 – 2005-12 · Type 2 Diabetes Mellitus
What this study did
NCT00372086 · The University of New South Wales
2003-08 – 2005-09 · Type 1 Diabetes, Puberty: >Tanner 2 Breast Development or Testis >4ml
What this study did
NCT00304993 · Foundation Research, Florida
2001-01 – 2005-02 · Metabolic Syndrome X, Insulin Resistance
What this study did
NCT00306644 · GlaxoSmithKline
2002-05 – 2004-11 · Diabetes Mellitus, Type 2
What this study did
NCT00290394 · Baskent University
2004-03 – 2004-08 · Diabetes Mellitus, Type 2
What this study did
NCT00329225 · GlaxoSmithKline
2002-09 – 2004-04 · Diabetes Mellitus, Type 2
What this study did
NCT00306696 · GlaxoSmithKline
2002-10 – 2004-01 · Diabetes Mellitus
What this study did
NCT00044460 · GlaxoSmithKline
2002-05 – 2003-04-10 · Diabetes Mellitus, Type 2
What this study did
NCT00501020 · GlaxoSmithKline
2001-06-05 – 2003-02-13 · Diabetes Mellitus, Type 2
What this study did
NCT00333723 · GlaxoSmithKline
2000-07-28 – 2003-01-06 · Diabetes Mellitus, Type 2
What this study did
NCT00358124 · Sanofi
2001-01 – 2002-06 · Type 2 Diabetes Mellitus
What this study did
NCT02526615 · Turku University Hospital
2000-10 – 2001-12 · Insulin Sensitivity, Type 2 Diabetes
What this study did
Early phase / not applicable (28)
Other / comorbidity
NCT02694874 · Centro de Investigacao em Saude de Manhica
2016-02 – 2021-12 · Malaria
What this study did
NCT01019356 · Jean-Patrice Baillargeon
2006-08 – 2021-07 · Polycystic Ovary Syndrome
What this study did
NCT03309319 · Zhaoyun Zhang
2016-10-16 – 2018-12-31 · Pituitary Tumor
What this study did
NCT00577590 · Washington University School of Medicine
2003-10 – 2012-09 · Diabetes Mellitus, Type II
What this study did
NCT00324675 · Technische Universität Dresden
2006-08 – 2010-12 · Type 2 Diabetes, Overt Diabetic Nephropathy
What this study did
NCT00252499 · US Department of Veterans Affairs
2005-10 – 2010-08 · Fatty Liver, Insulin Resistance
What this study did
NCT00143624 · University of British Columbia
2003-06 – 2009-12 · Atherosclerosis, HIV Infections
What this study did
NCT00242619 · Stanford University
2007-07 – 2009-12 · Depression, Bipolar Disorder, Insulin Resistance
What this study did
NCT00486187 · Dr. Milan Gupta
2006-04 – 2009-06 · Type 2 Diabetes Mellitus
What this study did
NCT00348309 · GlaxoSmithKline
2006-07-06 – 2009-01-28 · Alzheimer's Disease
What this study did
NCT00636766 · Aristotle University Of Thessaloniki
2005-09 – 2009-01 · Carotid Atherosclerosis, Stroke, Type 2 Diabetes, Metabolic Syndrome
What this study did
NCT00413335 · Yale University
2005-11 – 2008-12 · Obesity, Impaired Glucose Tolerance, Type 2 Diabetes Mellitus
What this study did
NCT00194896 · University of Washington
2000-02 – 2008-12 · Type 2 Diabetes Mellitus
What this study did
NCT00516880 · Hospital Authority, Hong Kong
2006-03 – 2008-11 · Chronic Disease, Kidney Diseases, Cardiovascular Diseases
What this study did
NCT00166803 · National Taiwan University Hospital
2005-06 – 2008-11 · Diabetes Mellitus, Atherosclerosis
What this study did
NCT00186537 · Stanford University
2003-09 – 2008-09 · Insulin Resistance, Hypertriglyceridemia
What this study did
NCT00466713 · Stanford University
2007-03 – 2007-12 · Dilated Cardiomyopathy
What this study did
NCT00282945 · Pfizer
2006-01 – 2007-10 · Type 2 Diabetes Mellitus
What this study did
NCT00264251 · St. Luke's-Roosevelt Hospital Center
2005-07 – 2007-08 · HIV Infections, Insulin Resistance, Obesity
What this study did
NCT00483392 · University Medical Centre Ljubljana
— · Insulin Resistance
What this study did
NCT00549874 · University of Michigan
2002-02 – 2006-11 · Type 2 Diabetes
What this study did
NCT00285805 · Radboud University Medical Center
2006-02 – 2006-11 · Insulin Resistance
What this study did
NCT00154011 · Technische Universität Dresden
2005-09 – 2006-06 · Healthy Subjects
What this study did
NCT00015691 · National Institute of Allergy and Infectious Diseases (NIAID)
est. completion 2006-01 · HIV Infections, Lipodystrophy, Hyperinsulinemia
What this study did
NCT00225225 · Stanford University
2002-10 – 2005-09 · Diabetes Mellitus, Type 2
What this study did
NCT00025753 · National Center for Research Resources (NCRR)
— · HIV Infections, Insulin Resistance
What this study did
NCT00285142 · University Hospital, Montpellier
2004-06 – 2004-11 · Healthy
What this study did
Used as active comparator (6)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (5)
Other / comorbidity
NCT00343980 · Novo Nordisk A/S
2006-10-10 – 2008-03-10 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00361868 · Solvay Pharmaceuticals
2006-06 – 2007-12 · Dyslipidemia, Glucose Metabolism Disorder
What this study did
NCT00541775 · Merck Sharp & Dohme LLC
2006-06 – 2007-03 · Type 2 Diabetes Mellitus
What this study did
NCT00331487 · Takeda
2000-09 – 2004-03 · Diabetes Mellitus
What this study did
Phase 4 (1)
Other / comorbidity
NCT00819910 · Ahmad Slim
2008-09 – 2010-05 · Hypertriglyceridemia in Type 4 Hyperlipidemia, Non Diabetic Subjects With Normoglycemia
What this study did
Appears in other studies (5)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (3)
Other / comorbidity
NCT00680745 · AstraZeneca
2008-04 – 2010-05 · Type 2 Diabetes
What this study did
NCT00295633 · AstraZeneca
2006-03 – 2008-10 · Diabetes Mellitus, Type 2
What this study did
NCT00350779 · Merck Sharp & Dohme LLC
2006-06-12 – 2008-06-11 · Type 2 Diabetes Mellitus
What this study did
Phase 1 (2)
Other / comorbidity
NCT00692510 · AstraZeneca
2007-11 – 2008-09 · Metabolism, Alzheimer's Disease
What this study did
NCT00232362 · Texas Tech University Health Sciences Center
2007-06 – 2008-06 · Type 2 Diabetes Mellitus
What this study did

Competitive landscape

3 other tracked programmes target this mechanism, 1 of them ahead of this one.

This drug's own stage for Asthma: Discontinued. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Rosiglitazone (Avandia): this drugDiscontinuedSmall moleculePPAR-gammanot yet gradedNo reviewed efficacy summary in this indication
Albuterol (Armstrong Albuterol HFA)ApprovedSmall moleculeBeta-2 adrenergic receptorPartial signalNo reviewed efficacy summary in this indication
Albuterol (Ventolin)ApprovedSmall moleculeBeta-2 adrenergic receptorWeak signalNo reviewed efficacy summary in this indication
Albuterol / Budesonide (Airsupra)ApprovedCombinationBeta-2 adrenergic receptor, Glucocorticoid receptorReliable signal
NCT05505734: Time to First Severe Asthma Exacerbation, While on Treatment Strategy, Interim Analysis Data Cut-off (Participants Aged >=12 Years) (From treatment initiation until the earliest occurrence of study completion, treatment discontinuation, step-up in maintenance therapy, or interim analysis DCO, up to one year following treatment initiation.): BDA MDI (PT027) 160/180 μg 62/1209 vs AS MDI (PT007) 180 µg 110/1212
NCT03769090: Number of Participants With a Severe Asthma Exacerbation Event (From randomization up to a discontinuation of randomized treatment or a change in maintenance therapy. The mean and median reporting period for all participants was 44 and 48 weeks, respectively.): BDA MDI 160/180 μg (Full Analysis Set; >=12 Years) 207/1013 | BDA MDI 80/180 μg (Full Analysis Set) 241/1054 vs AS MDI 180 μg (Full Analysis Set; >=12 Years) 266/1014 | AS MDI 180 μg (Full Analysis Set) 276/1056
Albuterol Sulfate (Amphastar)ApprovedSmall moleculeBeta-2 adrenergic receptornot yet gradedNo reviewed efficacy summary in this indication
Albuterol Sulfate (Proventil HFA)ApprovedSmall moleculeBeta-2 adrenergic receptornot yet gradedNo reviewed efficacy summary in this indication
AminophyllineApprovedSmall moleculePhosphodiesterase (multi-subtype)not yet gradedNo reviewed efficacy summary in this indication
Beclomethasone (QVAR)ApprovedSmall moleculeGlucocorticoid receptorReliable signal
NCT02040766: Baseline-adjusted trough morning percent predicted FEV1, AUEC(0-12 wk) vs placebo: BDP 80 ug/day BAI +2.81 (95% CI 0.80 to 4.82), p=0.0063; BDP 160 ug/day BAI +0.63, p=0.5332; BDP 80 ug/day MDI +0.92, p=0.3649; BDP 160 ug/day MDI +1.09, p=0.2823 (CT.gov posted results).
Beclomethasone Dipropionate / Formoterol Fumarate / Glycopyrrolate (Trimbow)
ApprovedUS marketing discontinued
Small moleculeGlucocorticoid receptor / Beta-2 adrenergic receptor / Muscarinic M3 receptor (ICS/LABA/LAMA triple combination)Reliable signalNo reviewed efficacy summary in this indication
Benralizumab (Fasenra)ApprovedMonoclonal antibodyIL-5 receptor alpha, IL-5 receptor alpha (IL-5Rα / CD125); Fc region additionally engages FcγRIIIa on NK cells (ADCC), IL-5 receptor alpha (IL5RA) on eosinophils/basophilsReliable signal
NCT03170271: Annualized Rate of Asthma Exacerbations Over the Treatment Period (up to Week 24) (Baseline (Week 0) up to Week 24): Benralizumab 0.94 Events/year (95% CI 0.79 to 1.12) | Placebo 1.86 Events/year (95% CI 1.54 to 2.24)
NCT01928771: Annual asthma exacerbation rate: 0.73 events/year with benralizumab 30 mg q4w vs 1.33 with placebo (rate ratio 0.55, 95% CI 0.42-0.71; p<0.001); 0.65 events/year with benralizumab 30 mg q8w vs 1.33 with placebo (rate ratio 0.49, 95% CI 0.37-0.64; p<0.001).
Budesonide (Pulmicort)ApprovedSmall moleculeGlucocorticoid receptor agonistnot yet gradedNo reviewed efficacy summary in this indication
Budesonide (Pulmicort Flexhaler)ApprovedSmall moleculeGlucocorticoid receptor agonistnot yet gradedNo reviewed efficacy summary in this indication
Budesonide / Formoterol Fumarate (SYMBICORT)ApprovedCombinationGlucocorticoid receptor; Beta-2 adrenergic receptorPartial signal
NCT00646321: Evening PEF (primary) better with once- or twice-daily budesonide/formoterol than budesonide alone (P<or=.027).
Budesonide / Glycopyrrolate / Formoterol Fumarate (Breztri Aerosphere)ApprovedSmall moleculeGlucocorticoid receptor; Muscarinic M3; Beta-2 adrenergicPartial signal
NCT04609878: Change From Baseline in FEV1 AUC0-3 (L) at Week 24 (Week 24): BGF MDI 320/14.4/9.6 μg BID 0.281 Liters (Standard Error 0.018) | BGF MDI 320/28.8/9.6 μg BID 0.316 Liters (Standard Error 0.014) vs BFF MDI 320/9.6 μg BID 0.249 Liters (Standard Error 0.014) | Symbicort® pMDI 320/9 μg BID 0.22 Liters (Standard Error 0.014)
NCT04609904: Change From Baseline in FEV1 AUC0-3 (L) at Week 24 (Week 24): BGF MDI 320/14.4/9.6 μg BID 0.374 Liters (Standard Error 0.019) | BGF MDI 320/28.8/9.6 μg BID 0.354 Liters (Standard Error 0.015) vs BFF MDI 320/9.6 μg BID 0.219 Liters (Standard Error 0.015) | Symbicort® 320/9 μg BID 0.239 Liters (Standard Error 0.015)
Ciclesonide (Alvesco)ApprovedSmall moleculeGlucocorticoid receptorReliable signal
NCT00174720: FEV1 change from baseline, source's own labeled primary endpoint (average of weeks 12 and 16): ciclesonide 80mcg b.i.d. +0.30L (p<0.0001), 160mcg q.d. +0.19L (p<0.0001), 80 b.i.d./160 q.d. stepped +0.19L (p<0.0001), vs placebo +0.06L (p=0.0251); at week 16 alone, all ciclesonide arms significant vs placebo (p<=0.015), magnitude not given for week 16 alone
NCT00163397: Change in FEV1: non-inferiority of ciclesonide to budesonide demonstrated (one-sided p = 0.0021), confirmed in the ITT analysis
DepemokimabApprovedMonoclonal antibodyIL-5Partial signal
NCT04719832: Annualized Rate of Clinically Significant Exacerbations up to 52 Weeks (Up to Week 52): Placebo 1.11 Exacerbation per participant per year (95% CI 0.86 to 1.43) | GSK3511294 0.46 Exacerbation per participant per year (95% CI 0.36 to 0.58)
Dupilumab (Dupixent)ApprovedMonoclonal antibodyIL-4R-alphaPartial signal
NCT03782532: Change in pre-bronchodilator FEV1, baseline to Week 12: LS mean difference 0.31 L favoring dupilumab vs placebo (95% CI 0.23-0.39); p<0.0001 (primary analysis population, n=414).
Fluticasone Furoate (Arnuity Ellipta)ApprovedSmall moleculeGlucocorticoid receptorPartial signal
NCT00603278: Mean Change From Baseline in Trough (Evening Pre-dose and Pre- Rescue Bronchodilator) FEV1 at Week 8 (Baseline and Week 8): GW685698X 100 µg OD 0.142 Liters (Standard Error 0.0403) | GW685698X 200 µg OD 0.173 Liters (Standard Error 0.0404) | GW685698X 300 µg OD 0.228 Liters (Standard Error 0.0402) | GW685698X 400 µg OD 0.215 Liters (Standard Error 0.0414) vs Placebo -0.065 Liters (Standard Error 0.0395) | FP 250 µg BID 0.16 Liters (Standard Error 0.0409)
NCT00603382: Mean Change From Baseline in Trough (Evening Pre-dose and Pre- Rescue Bronchodilator) FEV1 at Week 8 (Baseline and Week 8): GW685698X 25 µg OD 0.239 Liters (Standard Error 0.0428) | GW685698X 50 µg OD 0.266 Liters (Standard Error 0.042) | GW685698X 100 µg OD 0.341 Liters (Standard Error 0.0396) | GW685698X 200 µg OD 0.367 Liters (Standard Error 0.0428) vs Placebo 0.137 Liters (Standard Error 0.0428) | FP 100 µg BID 0.243 Liters (Standard Error 0.0411)
Fluticasone Furoate / Umeclidinium / Vilanterol (Trelegy Ellipta)ApprovedSmall moleculeMuscarinic acetylcholine receptor (M3), Beta-2 adrenergic receptor, Glucocorticoid receptor, Glucocorticoid receptor / Beta-2 adrenergic receptor / Muscarinic M3 receptor (ICS/LABA/LAMA triple combination)Reliable signal
NCT02924688: Week 24 trough FEV1: FF/UMEC/VI vs FF/VI treatment differences 0.096 L (95% CI 0.052 to 0.139; p<0.001), 0.110 L (95% CI 0.066 to 0.153; p<0.001), 0.082 L (95% CI 0.039 to 0.125; p<0.001), and 0.092 L (95% CI 0.049 to 0.135; p<0.001).
NCT04937387: Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 12 (100ug FF) (Baseline (pre-dose at Day 1) and Week 12): Fluticasone Furoate [FF] 100 ug/ Umeclidinium [UMEC] 62.5 ug/ Vilanterol [VI] 25 ug 0.136 Liters (Standard Error 0.0316) vs Fluticasone Furoate [FF] 100 Microgram[ug] / Vilanterol [VI] 25 ug 0.078 Liters (Standard Error 0.0321)
Fluticasone Furoate / Vilanterol (Breo Ellipta)ApprovedSmall moleculeBeta-2 adrenergic receptor, Glucocorticoid receptor, Glucocorticoid receptor / Beta-2 adrenergic receptorReliable signal
NCT01086384: Number of Participants With 1 or More Severe Asthma Exacerbations (Baseline to Follow-up (up to 76 weeks of treatment)): FF/VI 100/25 µg 154/1009 vs FF 100 µg 186/1010
NCT03248128: Absolute Weighted Mean of Forced Expiratory Volume in 1 Second (FEV1) (0-4 Hours) at Week 12 in 5-17 Year Old Population (Week 12): Participants Who Received FF/ VI FDC 2.082 Liters (Standard Deviation 0.7598) vs Participants Who Received FF 1.994 Liters (Standard Deviation 0.6998)
Fluticasone PropionateApprovedSmall moleculeGlucocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
Fluticasone Propionate / Salmeterol (Advair Diskus)ApprovedSmall moleculeGlucocorticoid receptor / Beta-2 adrenergic receptorPartial signal
NCT00920959: Change in percent predicted PM PEF: FSC 100/50 QD did not give significantly greater improvement than FP 100 QD (superiority not shown) missed
Fluticasone Propionate / Salmeterol (Advair HFA)ApprovedCombinationGlucocorticoid receptor / Beta-2 adrenergic receptor, Beta-2 adrenergic receptor, Glucocorticoid receptorPartial signal
NCT00448435: Adjusted Mean Change From Baseline in Morning PEF (Peak Expiratory Flow) During the 4-week Treatment Periods (Crossover Period Weeks 1-4, and 7-10): SFC 50/100 Mcg/Day 14.3 Liters/minute (Standard Error 4.53) vs SLM 50 Mcg + FP 100 Mcg/Day 17.1 Liters/minute (Standard Error 4.53)
Levalbuterol (Xopenex HFA)Approved—beta-2 adrenergic receptornot yet gradedNo reviewed efficacy summary in this indication
Mepolizumab (Nucala)ApprovedMonoclonal antibodyIL-5, Interleukin-5 (IL-5), ligand-neutralizingWeak signal
NCT01691508: Number of Participants With the Indicated Percent Reduction From Baseline in Oral Corticosteroid (OCS) Dose During Weeks 20 to 24 While Maintaining Asthma Control (Baseline; Weeks 20 to 24): Mepolizumab 100 mg SC — 90 to 100%: 16/69; 75 to <90%: 12/69; 50 to <75%: 9/69; >0 to <50%: 7/69; No decrease /lack of asthma control/early WD: 25/69 vs Placebo — 90 to 100%: 7/66; 75 to <90%: 5/66; 50 to <75%: 10/66; >0 to <50%: 7/66; No decrease /lack of asthma control/early WD: 37/66
NCT01000506: Number of Clinically Significant Exacerbations of Asthma Per Year (From randomization (Week 0) to Week 52 or early withdrawal (EW)): Mepolizumab 75 mg IV 1.24 Exacerbations per year | Mepolizumab 250 mg IV 1.46 Exacerbations per year | Mepolizumab 750 mg IV 1.15 Exacerbations per year vs Placebo IV 2.4 Exacerbations per year
MethylprednisoloneApprovedSmall moleculeGlucocorticoid receptor agonistnot yet gradedNo reviewed efficacy summary in this indication
Mometasone Furoate / Formoterol Fumarate (Dulera / Zenhale)ApprovedSmall moleculeGlucocorticoid receptor; Beta-2 adrenergic receptorPartial signal
NCT00383240: Primary endpoint (FEV1 AUC(0-12h) change from baseline to week 12, L*h), MF/F 200/10 mcg vs MF 200 mcg alone: 3.19 (SD 3.98) vs 1.31 (SD 3.98); p<.001.
NCT00383552: AUC(0-12h) change from baseline to Week 12 in FEV1: MF/F 100/10 mcg BID +4.00 L*h (SD 3.71) vs MF 100 mcg BID +2.53 L*h (SD 3.71); ANCOVA p=0.001.
Montelukast (Singulair)ApprovedSmall moleculeCysteinyl leukotriene receptor 1 (CysLT1)Weak signal
NCT00489346: Primary endpoint (percentage of asthma rescue-free days over 12 months): montelukast 5mg QD (n=495) was non-inferior to fluticasone 100mcg BID (n=499) — 495+499=994, exactly matching this record's enrollment. LS mean difference -2.8% (95% CI -4.7% to -0.9%), within the pre-specified -7% noninferiority margin.
Omalizumab (Xolair)ApprovedMonoclonal antibodyIgE (immunoglobulin E), IgEWeak signalNo reviewed efficacy summary in this indication
Primatene MistApprovedSmall moleculeAdrenergic receptor (non-selective, alpha+beta), Alpha-1 and beta-1/beta-2 adrenergic receptors, Adrenergic receptors, nonselectivePartial signal
NCT01460511: Primary endpoint, AUC0-6h of percent change in FEV1 at week 4: numerical benefit of epinephrine HFA over placebo, not statistically significant (two-sided p=0.125, per-protocol analysis; supported by the ITT and three sensitivity analyses). FDA judged the trial underpowered. missed
NCT01357642: Primary endpoint, AUC0-6h of percent change in FEV1 at week 12 (ITT): epinephrine HFA 250 mcg 40.59 (SD 56.09, n=248) vs placebo 12.76 (SD 55.77, n=61); mean difference 27.83 (95% CI 11.99 to 43.68), p<0.05. Epinephrine CFC active control: 35.67 (SD 45.70, n=64).
Salmeterol (DISKUS)ApprovedSmall moleculeBeta-2 adrenergic receptornot yet gradedNo reviewed efficacy summary in this indication
TerbutalineApprovedSmall moleculeBeta-2 adrenergic receptor (ADRB2)not yet gradedNo reviewed efficacy summary in this indication
Tezepelumab (Tezspire)ApprovedMonoclonal antibodyTSLP, Thymic stromal lymphopoietin (TSLP), ligand-neutralizingReliable signal
NCT03347279: Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma (From randomisation to Study Week 52.): Tezepelumab 210mg Q4W 0.93 events per year (95% CI 0.8 to 1.07) | Placebo 2.1 events per year (95% CI 1.84 to 2.39)
NCT03406078: Categorized Percent Reduction From Baseline in the Daily OCS Dose While Not Losing Asthma Control (Baseline to Week 48): Tezepelumab — >=90% to <=100% reduction: 40/74; >=75% to <90% reduction: 5/74; >=50% to <75% reduction: 10/74; >0% to <50% reduction: 5/74; no change or any increase: 14/74 vs Placebo — >=90% to <=100% reduction: 35/76; >=75% to <90% reduction: 4/76; >=50% to <75% reduction: 14/76; >0% to <50% reduction: 9/76; no change or any increase: 14/76 missed
Tiotropium BromideApprovedSmall moleculeMuscarinic acetylcholine receptor (M3)Reliable signal
NCT00772538: Peak Forced Expiratory Volume in 1 Second (FEV1) Response Within 3 Hours Post Dosing (0-3h) After a Treatment Period of 24 Weeks. (Baseline and 24 weeks): Tio R5 0.401 Liter (Standard Error 0.025) vs Placebo 0.315 Liter (Standard Error 0.026)
NCT00565266: Change Between Week 14 and Week 0 in the Morning (AM) Peak Expiratory Flow (PEF) (AM PEF was measured daily during each of the three 14-week treatment periods. The primary analysis constructed the change between week 14 and week 0.): Tio + 1xICS 24.4 Liters per minute (Standard Error 4.2) vs LABA + 1xICS 18 Liters per minute (Standard Error 3.2) vs 2xICS -1.4 Liters per minute (Standard Error 3.5)
Beclomethasone Dipropionate / Formoterol FumaratePhase 3Small moleculeGlucocorticoid receptor; β2-adrenergic receptorReliable signal
NCT05292586: 1_Change From Baseline in FEV1 AUC0-12h Normalised by Time at Week 12 (Baseline (pre-dose on Week 0) and Week 12.): CHF 1535 pMDI 0.279 liter (95% CI 0.248 to 0.309) vs CHF 718 pMDI 0.174 liter (95% CI 0.143 to 0.206)
FelcorekibartPhase 3Monoclonal antibodyTSLPnot yet gradedNo reviewed efficacy summary in this indication
FenoterolPhase 3Small moleculeBeta-2 adrenergic receptorPartial signalNo reviewed efficacy summary in this indication
Fenoterol / Ipratropium BromidePhase 3Small moleculeMuscarinic M3 receptor / Beta-2 adrenergic receptor (combination), Muscarinic acetylcholine receptor M3 and beta-2 adrenergic receptorReliable signal
NCT02182479: Primary, average FEV1 change from test-day baseline over 6 hours after dosing on day 85, non-inferiority of Respimat SMI (10/25 mcg and 20/50 mcg) vs pMDI (20/50 mcg): neither Respimat dose was inferior to the pMDI (p<0.001), met. Supportive: mean peak FEV1 increase on day 85 was 0.498 to 0.521 L with active treatment vs 0.215 and 0.240 L with placebo.
Indacaterol Maleate / Mometasone FuroatePhase 3—Glucocorticoid receptor / Beta-2 adrenergic receptorPartial signal
NCT02554786: Trough Forced Expiratory Volume in One Second (Trough FEV1) at Week 26 (26 weeks): QMF149 150/320 μg 2.383 litre (L) (Standard Error 0.0159) | QMF149 150/160 μg 2.387 litre (L) (Standard Error 0.016) | MF 800 μg 2.25 litre (L) (Standard Error 0.0162) | MF 400 μg 2.176 litre (L) (Standard Error 0.0162) | Salmeterol/Fluticasone 50/500 μg 2.346 litre (L) (Standard Error 0.016)
NCT02892344: Trough FEV1 (week 12): QMF149 150/80 μg 2.562 Liters (Standard Error 0.0134) | MF 200 µg 2.379 Liters (Standard Error 0.0134)
IpratropiumPhase 3Small moleculeMuscarinic acetylcholine receptor (M3)Weak signalNo reviewed efficacy summary in this indication
MasitinibPhase 3Small moleculeKIT (c-Kit), also PDGFR and Lyn/Fyn kinasesPartial signal
NCT01449162: Annualized severe asthma exacerbation rate (SAER), primary population, overall treatment exposure: masitinib reduced SAER by 35% vs placebo; rate ratio 0.65 (95% CI 0.47-0.90; P=0.010)
NCT03771040: Severe asthma exacerbations: 29% reduction vs placebo (p=0.022) in patients with eosinophils above 150/uL
OcankitugPhase 3Monoclonal antibodyTSLPnot yet gradedNo reviewed efficacy summary in this indication
Oxitropium Bromide (Ba253BINEB)Phase 3Small moleculeMuscarinic acetylcholine receptor (M3)Weak signalNo reviewed efficacy summary in this indication
RademikibartPhase 3Monoclonal antibodyIL-4R-alphanot yet gradedNo reviewed efficacy summary in this indication
Salbutamol HFA-152aPhase 3Small moleculeBeta-2 adrenergic receptorWeak signal
NCT06261957: Primary outcomes, safety (no formal efficacy test): participants with an adverse event in the treatment period 108/338 (HFA-152a) vs 36/112 (HFA-134a); none in the run-in period (0/471); serious adverse events 6/338 vs 3/112 (CT.gov posted results).
TilrekimigPhase 3Multispecific antibodyIL-4/IL-13/TSLPnot yet gradedNo reviewed efficacy summary in this indication
VilanterolPhase 3Small moleculeBeta-2 adrenergic receptorPartial signal
NCT00600171: Mean Change From Baseline in Clinic Visit Trough FEV1 at Day 28 (Last Observation Carried Forward [LOCF]) (Baseline and Day 28): GW642444M 3 µg 0.212 Liters (Standard Error 0.036) | GW642444M 6.25 µg 0.217 Liters (Standard Error 0.035) | GW642444M 12.5 µg 0.278 Liters (Standard Error 0.036) | GW642444M 25 µg 0.269 Liters (Standard Error 0.035) | GW642444M 50 µg 0.309 Liters (Standard Error 0.035) vs Placebo 0.147 Liters (Standard Error 0.036)
Glycopyrronium (PT001)Phase 2/3Small moleculeMuscarinic acetylcholine receptor (M3)Partial signal
NCT03358147: Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve From 0 to 4 Hours (AUC0-4) (Week 24): GP MDI 28.8 μg 0.294 Liter (95% CI 0.248 to 0.341) | GP MDI 14.4 μg 0.284 Liter (95% CI 0.238 to 0.331) | GP MDI 7.2 μg 0.308 Liter (95% CI 0.263 to 0.354) vs Placebo MDI 0.24 Liter (95% CI 0.194 to 0.287) | Spiriva Respimat 2.5 μg 0.347 Liter (95% CI 0.282 to 0.412)
StapokibartPhase 2/3Monoclonal antibodyIL-4R-alphanot yet gradedNo reviewed efficacy summary in this indication
WIN378Phase 2/3Monoclonal antibodyTSLPWeak signalFeatured results are safety only in this race
AK139Phase 2Multispecific antibodyIL-4 receptor alpha / ST2not yet gradedNo reviewed efficacy summary in this indication
ARO-RAGEPhase 2RNA / oligonucleotideRAGE (receptor for advanced glycation end-products)Weak signalFeatured results are safety only in this race
BrenipatidePhase 2PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
CM512Phase 2Multispecific antibodyTSLP + IL-13not yet gradedNo reviewed efficacy summary in this indication
ENV-294Phase 2Small molecule—not yet gradedNo reviewed efficacy summary in this indication
Freneslerbart / MevonlerbartPhase 2Monoclonal antibodyFel d 1 (major cat allergen protein)Reliable signal
NCT03838731: Primary endpoint, time to early asthmatic reaction at Week 1 following single dose: >4 hours (REGN1908-1909) vs 51 minutes (placebo), p=0.0083
FrevecitinibPhase 2Small moleculeJAK1/2/3/TYK2Weak signalNo reviewed efficacy summary in this indication
KT-621Phase 2Small moleculeSTAT6not yet gradedNo reviewed efficacy summary in this indication
LunsekimigPhase 2Antibody-derived scaffoldTSLP + IL-13Weak signalFeatured results are safety only in this race
PBF-680Phase 2—Adenosine A1 receptorPartial signal
NCT03774290: Trough FEV1 change from baseline at Day 16: placebo 2.88±0.10 L vs PBF-680 3.06±0.09 L; +180 mL mean increase over placebo (P=0.0816, pre-specified alpha=0.1)
QuisovalimabPhase 2Monoclonal antibodyLIGHT (TNFSF14)Partial signal
NCT05288504: Participants with an asthma-related event through week 14: AVTX-002 12 vs placebo 14 (CT.gov posted counts); the sponsor states the primary endpoint was not met. missed

Large race: only the 60 furthest-along competitors are listed; 27 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

No upcoming readouts on record for this asset.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

3 September 2025WithdrawalFDA withdraws approval of NDA 021071 (Federal Register 2025-14683)
US, FDA · Source ↗